CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.21 USD
+0.02 (1.68%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.20 -0.01 (-0.83%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.21 USD
+0.02 (1.68%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.20 -0.01 (-0.83%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Zacks News
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
by Zacks Equity Research
Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
by Zacks Equity Research
After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
by Zacks Equity Research
Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
by Zacks Equity Research
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
by Zacks Equity Research
Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug
by Zacks Equity Research
The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.
J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag
by Zacks Equity Research
FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry
by Zacks Equity Research
Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
by Zacks Equity Research
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
by Zacks Equity Research
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study
by Zacks Equity Research
Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.
FDA Accepts Karuna's (KRTX) NDA Filing for Schizophrenia Drug
by Zacks Equity Research
If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. A final decision is expected in September 2024.
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
by Zacks Equity Research
Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.
Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
by Zacks Equity Research
The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.
Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data
by Zacks Equity Research
Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
by Zacks Equity Research
The FDA approves SpringWorks' (SWTX) Ogsiveo (nirogacestat) for the treatment of adult patients with desmoid tumors. Shares rise.
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
by Zacks Equity Research
Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug
by Zacks Equity Research
The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.
GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study
by Zacks Equity Research
GSK announces positive data from the DREAMM-7 head-to-head phase III study evaluating Blenrep for second-line treatment of relapsed or refractory multiple myeloma. The study meets its primary endpoint.
CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here's Why
by Zacks Equity Research
CRISPR (CRSP) expects a potential approval for its gene-edited therapy, Casgevy (exa-cel) in the United States for treating two debilitating blood disorders. The drug has been recently approved in the United Kingdom.
Vertex (VRTX) Gets EU Nod for Kaftrio Use in 2-5 Year Kids
by Zacks Equity Research
The European Commission approves Vertex's (VRTX) Kaftrio for expanded use to treat children aged two to five years with cystic fibrosis.
Freeline (FRLN) Shares Rise on Merger Agreement With Syncona
by Zacks Equity Research
Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down
by Zacks Equity Research
The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.
Here's Why You May Invest in Puma Biotechnology (PBYI) Stock
by Zacks Equity Research
Here, we discuss some reasons why investing in Puma Biotechnology (PBYI) stock now may turn out to be a more prudent move than ever.